Efficacy of Dydrogesterone in Threatened Miscarriage: a Systematic Review and Meta-analysis
https://doi.org/10.31550/1727-2378-2022-21-5-53-61
Abstract
Objective of the Review: To review all studies using dydrogesterone in threatened miscarriage and to evaluate the effect of dydrogesterone treatment on miscarriage rates in women with miscarriage.
Key points. Many years of experience in many clinical studies confirm that progestogens contribute to the preservation of pregnancy in the event of a threatened miscarriage. Dydrogesterone and progesterone are the most suitable progestogens for pregnant women. The high result of dydrogesterone in high-risk pregnancy is due to its chemical structure. This systematic review and meta-analysis includes data only from randomized trials, in particular those based on comparisons of dydrogesterone with placebo. The results demonstrate that in the group of patients treated with dydrogesterone, the frequency of miscarriages was statistically significantly lower than in the group of patients treated with placebo. These findings correlate with previous data from meta-analyses and reviews of randomized clinical trials in 2017–2021, where dydrogesterone also significantly reduced the risk of pregnancy loss in threatened and recurrent miscarriage. Moreover, the largest direct comparative randomized study IPD LOTUS (2020) demonstrated a higher efficacy of dydrogesterone compared to micronized vaginal progesterone.
Conclusion. According to the results of this systematic review and meta-analysis of randomized clinical trials based on the comparison of dydrogesterone with placebo, in the group of patients who received dydrogesterone, the frequency of miscarriages was statistically significantly lower than in the group of patients who received placebo. The use of dydrogesterone is not only justified, but an essential component of the treatment of recurrent pregnancy loss.
Keywords
miscarriage,
recurrent pregnancy loss,
habitual miscarriage,
progestagens,
dydrogesterone,
progesterone
Supporting agencies: This work was supported by the funding of the State Assignment No. 16-А21: “Development of a system for predicting complications and outcomes of pregnancy in women with recurrent miscarriage”.
About the Authors
N. K. Tetruashvili
FSBI “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after academician V.I. Kulakov” Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
4 Academician Oparin Str., Moscow, 117997
E. V. Shih
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
8 Trubetskaya Str., build. 2, Moscow, 119991
References
1. Hassan R., Baird D.D., Herring A.H., Olshan A.F. et al. Patterns and predictors of vaginal bleeding in the first trimester of pregnancy. Ann. Epidemiol. 2010; 20(7): 524–31. DOI: 10.1016/j.annepidem.2010.02.006
2. Quenby S., Gallos I.D., Dhillon-Smith R.K., Podesek M. et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021; 397(10285): 1658–67. DOI: 10.1016/S0140-6736(21)00682-6
3. Tetruashvili N.K., Agadzhanova A.A. Management of single and multiple pregnancy in women with habitual abortion. Obstetrics and Gynecology: News, Opinions, Training. 2018; 2: 52–7. (in Russian)
4. Savelyeva G.M., Sukhikh G.T., Serov V.N., Radzinsky V.E., eds. Obstetrics: a national guide. M.: GEOTAR-Media; 2018. 1088 p. (in Russian)
5. Tetruashvili N.K. Recurrent abortion. Obstetrics and Gynecology: News, Opinions, Training. 2017; 4: 70–87. (in Russian) DOI: 10.24411/2303-9698-2017-00010
6. Coomarasamy A., Devall A.J., Cheed V., Harb H. et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N. Engl. J. Med. 2019; 380(19): 1815–24. DOI: 10.1056/NEJMoa1813730
7. Shih E.V. Pharmacotherapy during pregnancy. M.: GEOTAR-Media; 2019. 208 p. (in Russian)
8. Benagiano G., Carrara S., Filippi V. Safety, efficacy and patient satisfaction with continuous daily administration of levononorgesterel/ethinylestradiol oral contraceptives. Patient Prefer. Adherence. 2009; 3: 131–43. DOI: 10.2147/ppa.s3692
9. Schindler A.E., Campagnoli C., Druckmann R., Huber J. et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1–2): 171–80. DOI: 10.1016/j.maturitas.2008.11.013
10. Kale A.R., Kale A.A., Yelikar K. A comparative, randomized control trial in patients of per vaginal bleeding comparing efficacy of oral dydrogesterone versus vaginal progesterone in successful pregnancy outcome for patients with recurrent pregnancy loss. J. Obstet. Gynecol. India. 2021; 71(6): 591–5. DOI: 10.1007/s13224-021-01473-2
11. Astrakhantseva M.M., Myasoutova A.I., Breusenko L.E., Shalina R.I. et al. Pregnancy loss. Treatment options. Gynecology, Obstetrics and Perinatology. 2021; 20(2): 75–84. (in Russian) DOI: 10.20953/1726-1678-2021-2-75-84
12. Griesinger G., Blockeel C., Kahler E., Pexman-Fieth C. et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: a systematic review and individual participant data meta-analysis. PLoS One. 2020; 15(11): e0241044. DOI: 10.1371/journal.pone.0241044
13. Shikh E.V. Clinical-pharmacological aspects of the use of dydrogesterone in pregnancy maintenance. Obstetrics, Gynecology and Reproduction. 2010; 4(2): 6–9. (in Russian)
14. Griesinger G., Tournaye H., Macklon N., Petraglia F. et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod. Biomed. Online. 2019; 38(2): 249–59. DOI: 10.1016/j.rbmo.2018.11.017
15. Schindler A.E., Campagnoli C., Druckmann R., Huber J. et al. Classification and pharmacology of progestins. Maturitas. 2003; 46(suppl.1): S7–16. DOI: 10.1016/j.maturitas.2003.09.014
16. Colombo D., Ferraboschi P., Prestileo P., Toma L. A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy. J. Steroid Biochem. Mol. Biol. 2006; 98(1): 56–62. DOI: 10.1016/j.jsbmb.2005.07.009
17. Rižner T.L., Brožič P., Doucette C., Turek-Etienne T. et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011; 76(6): 607–15. DOI: 10.1016/j.steroids.2011.02.043
18. Stanczyk F.Z., Hapgood J.P., Winer S., Mishell D.R. Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr. Rev. 2013; 34(2): 171–208. DOI: 10.1210/er.2012-1008
19. Tetruashvili N.K., Serov V.N. Gestagens in high-risk pregnancy. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10(2): 31–8. (in Russian) DOI: 10.33029/2303-9698-2022-10-2-31-38
20. Ehrenskjöld M.L., Bondo B., Weile F. Treatment of threatened abortion with dydrogesterone. Ugeskr. Laeg. 1967; 129(50): 1678–1679. [Article in Danish]
21. El-Zibdeh M.Y., Yousef L.T. Dydrogesterone support in threatened miscarriage. Maturitas. 2009; 65(suppl.1): S43–6. DOI: 10.1016/j.maturitas.2009.11.013
22. Omar M.H., Mashita M.K., Lim P.S., Jamil M.A. Dydrogesterone in threatened abortion: pregnancy outcome. J. Steroid Biochem. Mol. Biol. 2005; 97(5): 421–5. DOI: 10.1016/j.jsbmb.2005.08.013
23. Pandian R.U. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009; 65(suppl.1): S47–50. DOI: 10.1016/j.maturitas.2009.11.016
24. Gevorkyan M.A., Manukhin I.B., Manukhina E.I., Studenaya L.B. Efficiency of Duphaston in treating threatened miscarriage in early stages of pregnancy. Problems of Reproduction. 2004; 10(6): 63–64. (in Russian)
25. Li F.H. Evaluation of the effectiveness of progesterone in the prevention or treatment of pregnancy diseases. China Foreign Med. Treat. 2018; 34: 41–3. [Article in Chinese]
26. Chan D.M.K., Cheung K.W., Ko J.K.Y., Yung S.S.F. et al. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial. Hum. Reprod. 2021; 36(3): 587–95. DOI: 10.1093/humrep/deaa327
27. Czajkowski K., Sienko J., Mogilinski M., Bros M. et al. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil. Steril. 2007; 87(3): 613–18. DOI: 10.1016/j.fertnstert.2006.07.1506
28. Vincze E., Molnár B.G., Földesi I., Pál A. Treatment possibilities for threatened abortion using progesterone and progesterone-type drugs. J. Hungarian Gynaecol. 2006; 69: 281–4.
29. Siew J.Y.S., Allen J.C., Hui C.Y.Y., Ku C.Wai. et al. The randomized controlled trial of micronized progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur. J. Obstet. Gynecol. 2018; 228: 319–24. DOI: 10.1016/j.ejogrb.2018.07.028
30. Liu Y.Y. A randomized controlled study of dydrogesterone and progesterone capsules in the treatment of threatened abortion. Chinese J. Convalescent Med. 2016; 25(02): 214–15. [Article in Chinese]
31. Lin B.Z., Guo S.Y., Chen L.F. A randomized controlled study of dydrogesterone and progesterone in the treatment of threatened abortion. China Pract. Med. 2015; 10(34): 108–9. [Article in Chinese]
32. Tian Y.H. Clinical effect of dydrogesterone and progesterone on threatened abortion. J. Qiqihar University of Medicine. 2015; 36(21): 3194–5. [Article in Chinese]
33. Lin J.F. To explore the clinical efficacy of dydrogesterone in the treatment of threatened abortion. North. Pharmacy. 2013; 10(02): 25–6. [Article in Chinese]
34. Ru L. Clinical analysis of dydrogesterone in the treatment of threatened abortion. China Health Care Nutr. 2014; 24(3): 1691–2. [Article in Chinese]
35. Zhang J.Y. Clinical observation on 388 cases of threatened abortion treated with dydrogesterone. China Pharmacist. 2014; 17(06): 1006–7. [Article in Chinese]
36. Hu H.Y. Comparison of the efficacy and safety of dydrogesterone and progesterone in the treatment of threatened abortion. Good Health for All. 2015; 9(19): 121–2. [Article in Chinese]
37. Wu H.Q. Comparison of the clinical effect of dydrogesterone and progesterone capsule in the treatment of threatened abortion. Prescription Drugs in China. 2015; 13(07): 77–8. [Article in Chinese]
38. Yan W. Comparison of efficacy between dydrogesterone and progesterone in the treatment of threatened abortion. Contemporary Med. Forum. 2008; 16(22): 47–8. [Article in Chinese]
39. Yin J.J. Efficacy analysis of dydrogesterone in the treatment of early threatened abortion. Med. Forum. 2018; 22(34): 4813–15. [Article in Chinese]
40. Chen W.L. Comparison of the clinical effect of dydrogesterone and progesterone capsules in the treatment of threatened abortion. Med. Informatics. 2016; 29(18): 141–2. [Article in Chinese]
41. Qian Y.X. Comparative analysis of the clinical efficacy of dydrogesterone and progesterone capsules in the treatment of threatened abortion. Jia You Yun Bao. 2020; 2(6): 54–5. [Article in Chinese]
42. Lu Y.X. Comparative analysis of the efficacy of dydrogesterone and progesterone capsules in the treatment of threatened abortion. Chinese Baby. 2020; 1: 110. [Article in Chinese]
43. Chen L.H. Observation on the efficacy and Adverse reactions of dydrogesterone in the treatment of threatened abortion. Health Horizon. 2020; 5: 112. [Article in Chinese]
44. Huang L. A comparative study of dydrogesterone and progesterone capsules in the treatment of threatened abortion. Shanghai Med. Pharmaceut. J. 2019; 40(22): 24–5. [Article in Chinese]
45. Chang M.Z. Comparison of the clinical effect of dydrogesterone and progesterone capsule in the treatment of threatened abortion. J. North. Pharmacy. 2019; 16(1): 21. [Article in Chinese]
46. Chen J. Analysis of the clinical efficacy of progesterone capsule and dydrogesterone in the treatment of threatened abortion. Health Guide. 2017; 38: 27. [Article in Chinese]
47. Li S.P. Study on the value of dydrogesterone and progesterone capsules in the treatment of threatened abortion. Clin. Laboratory J. 2017; 6(02): 166–7. [Article in Chinese]
48. Liu Y.Y. Clinical value analysis of dydrogesterone and progesterone capsules in the treatment of threatened abortion. Drug Evaluation. 2016; 13(23): 46–8. [Article in Chinese]
49. Ye Q.C. Comparison of the efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. Med. Inform. 2016; 29(11): 212–13. [Article in Chinese]
50. Lou C., Wang C., Zhao Q., Jin F. Effect of dydrogesterone and progesterone on threatened miscarriage due to corpus luteum insufficiency. Am. J. Transl. Res. 2021; 13(5): 4544–52.
51. Dong J.F. Observation on the efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. China Modern Med. 2011; 18(18): 77–8. [Article in Chinese]
52. He T.F. Observation on the curative effect of dydrogesterone and progesterone on threatened abortion. China Foreign Med. Treat. 2012; 31(21): 101. [Article in Chinese]
53. Wei Y.L. Clinical comparison of dydrogesterone and progesterone in the treatment of threatened abortion. Chinese J. Clin. Rational Drug Use. 2013; 6(16): 38–9. [Article in Chinese]
54. Dai Z.G. Comparison of the efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. Chinese J. Clin. Rational Drug Use. 2013; 6(13): 99–100. [Article in Chinese]
55. Li J. Clinical comparison of dydrogesterone and progesterone in the treatment of threatened abortion. Nat. Med. Front. China. 2013; 8(23): 69–70. [Article in Chinese]
56. Chen L. Observation on the implementation effect of dydrogesterone and progesterone in the treatment of threatened abortion. Health Care Today. 2013; 7: 42. [Article in Chinese]
57. Zeng R.H. Observation on the efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. J. Gannan Medical University. 2014; 34(02): 280–2. [Article in Chinese]
58. Zhang Z.H. Clinical efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. J. Med. Theory Pract. 2015; 28(11): 1509–10. [Article in Chinese]
59. Wu Y.F. Observation on the efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. World Health Digest. 2014; 22: 104–5. [Article in Chinese]
60. Wu H.Q. Observation on the curative effect of dydrogesterone and progesterone on threatened abortion. Med. Informatics. 2015; 25: 330–1. [Article in Chinese]
61. Li Y.Q. Clinical comparison of dydrogesterone and progesterone in the treatment of threatened abortion. Yiyao Qianyan. 2016; 6(31): 109–10. [Article in Chinese]
62. Yao J. Comparative analysis of clinical efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. Chinese J. Modern Drug Application. 2017; 19: 137–8. [Article in Chinese]
63. Ding H.M. Observation on the efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. Psychol. Doctor. 2017; 23(25): 64–5. [Article in Chinese]
64. Yu Y. Analysis of the application value of dydrogesterone in the treatment of early threatened abortion. Contemporary Med. 2017; 28: 31–3. [Article in Chinese]
65. Chen L.Y., Cao H.X. Effect of dydrogesterone tablets in the treatment of threatened abortion and its influence on pregnancy outcome. Chinese Foreign Med. Res. 2018; 16(21): 4–7. [Article in Chinese]
66. Xu H.N. A comparative study on the effect of dydrogesterone and progesterone in the treatment of threatened abortion. J. Shanxi College of Traditional Chinese Medicine. 2018; 2: 47–8. [Article in Chinese]
67. Chang D. Clinical effect of dydrogesterone in the treatment of threatened abortion. Chinese J. Modern Drug Application. 2020; 14(03): 172–3. [Article in Chinese]
68. Zheng Y.M. Clinical effect of dydrogesterone in the treatment of threatened abortion. Guide China Med. 2019; 17(12): 119–20. [Article in Chinese]
69. Zhang Z.H. An analysis of the efficacy and safety of dydrogesterone tablets in the treatment of threatened abortion. Health Friend. 2019; 17: 139. [Article in Chinese]
70. Zhang L., Li Y.X. Clinical efficacy and safety of dydrogesterone and progesterone in the treatment of threatened abortion. Chinese Baby. 2019; 2: 132. [Article in Chinese]
71. Huang X.J., Jiang C. Clinical efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. Chinese Baby. 2019; 9: 25. [Article in Chinese]
72. Hu Y.J. Comparison of clinical efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. J. Med. Theory Pract. 2019; 32(17): 2785–6. [Article in Chinese]
73. Du Z. Comparison of the clinical efficacy of dydrogesterone and progesterone in the treatment of threatened abortion. Health Friend. 2019; 4: 20. [Article in Chinese]
74. Yu G.X. Comparison of the curative effect of dydrogesterone and progesterone in treating threatened abortion. Chinese Baby. 2018; 10: 120. [Article in Chinese]
75. Wahabi H.A., Fayed A.A., Esmaeil S.A., Bahkali K.H. Progestogen for treating threatened miscarriage. Cochrane Database Syst. Rev. 2018; 8(8): CD005943. DOI: 10.1002/14651858.CD005943.pub5
76. Wang X.X., Luo Q., Bai W.P. Efficacy of progesterone on threatened miscarriage: difference in drug types. J. Obstet. Gynaecol. Res. 2019; 45(4): 794–802. DOI: 10.1111/jog.13909
77. Lee H.J., Park T.C., Kim H.J., Norwitz E. et al. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. Biomed. Res. Int. 2017; 2017: 3616875. DOI: 10.1155/2017/3616875
78. Carp H.J.A. Progestogens and pregnancy loss. Climacteric. 2018; 21(4): 380–4. DOI: 10.1080/13697137.2018.1436166
79. Haas D.M., Hathaway T.J., Ramsey P.S. Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. Cochrane Database Syst. Rev. 2019; 11: CD003511. DOI: 10.1002/14651858.CD003511.pub5
80. Saccone G., Schoen C., Franasiak J.M., Scott R.T. Jr et al. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil. Steril. 2017; 107(2): 430–8. e3. DOI: 10.1016/j.fertnstert.2016.10.031
81. Li L., Zhang Y., Tan H., Bai Y. et al. Effect of progestogen for women with threatened miscarriage: a systematic review and meta-analysis. BJOG. 2020; 127(9): 1055–63. DOI: 10.1111/1471-0528.16261
82. Zhao H., He W., Yang Z. A pairwise and network meta-analysis comparing the efficacy and safety of progestogens in threatened abortion. Int. J. Gynaecol. Obstet. 2022; 156(3): 383–93. DOI: 10.1002/ijgo.13707
83. Kumar A., Begum N., Prasad S., Aggarwal S. et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil. Steril. 2014; 102(5): 1357–63.e3. DOI: 10.1016/j.fertnstert.2014.07.1251
84. Coomarasamy A., Williams H., Truchanowicz E., Seed P.T. et al. A randomized trial of progesterone in women with recurrent miscarriages (PROMISE). N. Engl. J. Med. 2015; 373(22): 2141–8. DOI: 10.1056/NEJMoa1504927
85. Tetruashvili N.K., Agadzhanova A.A. Dydrogesterone in the treatment of the threatened and habitual miscarriage. Medical Council. 2018; 13: 68–72. (in Russian) DOI: 10.21518/2079-701X-2018-13-68-72
Review
For citations:
Tetruashvili N.K., Shih E.V. Efficacy of Dydrogesterone in Threatened Miscarriage: a Systematic Review and Meta-analysis. Title. 2022;21(5):53-61. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-5-53-61
Views:
26
Email this article 